A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with multiple sclerosis (CFTY720D2399)
The purpose of this study is to collect long-term safety, tolerability, efficacy and health outcomes data in all patients previously or currently participating in the fingolimod multiple sclerosis clinical development program.
KeywordsSafety, outcomes, fingolimod multiple sclerosis, program
Principal InvestigatorScott Silliman, AST PROFESSOR
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.